StockNews.com began coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Free Report) in a research note issued to investors on Monday morning. The firm issued a buy rating on the biopharmaceutical company’s stock.
Acorda Therapeutics Price Performance
The company has a quick ratio of 0.26, a current ratio of 0.33 and a debt-to-equity ratio of 3.07. The firm has a market capitalization of $820,000.00, a PE ratio of 0.00 and a beta of 1.40. Acorda Therapeutics has a 52-week low of $0.61 and a 52-week high of $24.20. The stock’s fifty day moving average price is $10.27 and its 200-day moving average price is $11.87.
About Acorda Therapeutics
See Also
- Five stocks we like better than Acorda Therapeutics
- What is a Low P/E Ratio and What Does it Tell Investors?
- Lucid’s Stock Price is Still in Reverse: New Lows Are Coming
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Generac Powers Ahead on the Electrification Mega-Trend
- 5 discounted opportunities for dividend growth investors
- PulteGroup Wins and Wins More on Interest Rate Cuts
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.